A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Academic Article uri icon

Overview

MeSH Major

  • BRCA1 Protein
  • BRCA2 Protein
  • Breast Neoplasms
  • Germ-Line Mutation

abstract

  • BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.

publication date

  • October 24, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC314444

Digital Object Identifier (DOI)

  • 10.1186/bcr658

PubMed ID

  • 14680495

Additional Document Info

start page

  • R8

end page

  • R17

volume

  • 6

number

  • 1